Navigation Links
Neurochem reports results for third quarter of fiscal 2007
Date:11/7/2007

sion or compromise by Neurochem.

Reimbursable costs amounted to $73,000 for the current quarter ($332,000 for the nine-month period), compared to $152,000 for the same period in the previous year ($534,000 for the nine-month period), and consist of costs incurred on behalf of Centocor in respect of eprodisate (KIACTA(TM))-related activities and reimbursable by Centocor.

Stock-based compensation amounted to $998,000 for the current quarter ($2,854,000 for the nine-month period), compared to $948,000 for the corresponding quarter in the previous year ($2,645,000 for the nine-month period). This expense relates to stock options and stock-based incentives, whereby compensation cost in relation to stock options is measured at fair value at the date of grant and is expensed over the award's vesting period.

Interest income amounted to $1,021,000 for the current quarter ($2,585,000 for the nine-month period), compared to $429,000 for the same quarter in the previous year ($1,503,000 for the nine-month period). The increase is mainly attributable to higher average cash balances during the current periods, compared to the same periods in the previous year.

Accretion expense amounted to $1,452,000 for the current quarter ($14,568,000 for the nine-month period), and mainly represents the imputed interest under GAAP on the $42,085,000 aggregate principal amount of 6% convertible senior notes issued in November 2006, as well as on the $40,000,000 6% senior convertible notes (Senior Notes) and $40,000,000 5% senior subordinated convertible notes (Junior Notes) issued in May 2007. The Company accretes the carrying values of the convertible notes to their face value through a charge to earnings over their expected lives of 60 months, 54 months and 1 month, respectively. Of the total accretion expense recorded in the nine-month period ended September 30, 2007, $10,431,000 relates to accretion expense on the Junior Notes, which were fully converted during the s
'/>"/>

SOURCE NEUROCHEM INC.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine news :

1. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
2. Haemacure Reports Third Quarter 2007 Results
3. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
4. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
5. MDS Reports Third Quarter 2007 Results
6. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
7. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
8. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
9. Blue Cross and Blue Shield of Florida Reports Eighteenth Consecutive Year of Positive Performance
10. ReBuilder Medical Technologies, Inc. Reports International Sales Expansion
11. AdCare Health Systems, Inc. Reports Discontinuation of Definitive Merger Agreement with Family Home Health Services, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... July 31, 2015 , ... Creating one of the most modern fertility ... a visionary image that goes beyond the boundaries of fertility medicine. , As ... extraordinary heights with dependable patient support, affordable treatments, unending hope, and high fertility success ...
(Date:7/31/2015)... ... , ... The Mount Sinai Health System will work with Columbia Care LLC, ... experimental treatments. The collaboration moves into the next phase with the recent decision by ... state licenses to produce and dispense medical marijuana. , Mount Sinai and Columbia ...
(Date:7/31/2015)... ... July 31, 2015 , ... Recently, ZKB filed ... Ohio, Western Division (Case No. 3:15-cv-00397) involving the Implanon® contraceptive implant . ... migration of their Implanon® implants, inability to locate the implants, unsuccessful and invasive ...
(Date:7/31/2015)... ... 31, 2015 , ... Florida Hospital Tampa has started treating ... for targeted delivery of fluids to selected sites in the peripheral vascular system. ... with the device that provides direct, local delivery of chemotherapy to the pancreas. ...
(Date:7/31/2015)... ... 31, 2015 , ... Awarded to only the Top 10 hair transplant practices ... are the latest recipients of the Center of Clinical Excellence for ARTAS Robotic ... leaders in the science of hair transplant. , Parsa Mohebi Hair Restoration is known ...
Breaking Medicine News(10 mins):Health News:New Hope IVF Now Offers Most Affordable Assisted Reproductive Treatment in the UAE 2Health News:New Hope IVF Now Offers Most Affordable Assisted Reproductive Treatment in the UAE 3Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 2Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 3Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 2Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 3Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 2Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 3Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 4Health News:Prestigious Medical Award Given To Parsa Mohebi Hair Restoration for Excellence in Hair Transplantation 2
... GENCO Supply Chain Solutions, company, to present, ... during U.S. Environmental Protection Agency,s (Region III) Pharmaceutical ... ... Capital Returns, Inc. (CRI), the,pharmaceutical industry,s leading processor of ...
... WALNUT CREEK, Calif., June 5 Longs Drug,Stores Corporation (NYSE: LDG ) today reported preliminary total retail drug,store sales for the four-week and seventeen-week periods ended ... Periods ended ... ... (4 weeks) (17 weeks), Total retail drug ...
... OSHA ,Star Site, PITTSBURGH, June 5 ... Cranberry, Pa. manufacturing plant has been designated a,national ... Occupational,Safety and Health Administration (OSHA). Fewer than 85 ... the U.S. have earned,this distinction since the VPP ...
... Closer Look at The Value of,MRIs is now ... website, http://www.msassociation.org . This three part video,features: ... first-hand,account on the experience of undergoing an MRI; ... the importance of MRIs to monitor disease,progression; and ...
... Awarded Top Juice Beverage by Health Magazine, SEATTLE, ... and,juice producers, and its Yellow Mango Orchard natural 100 ... Buys in 2008 by Health,Magazine., With the help ... products in beauty, food and fitness to the ultimate ...
... 5 Benchmarking is not a luxury;,it is an ... research,excerpt presents a survey analysis of 30 companies and ... are using benchmarking in a,difficult economy., The complete ... to benchmark, the goals of benchmarking studies, how companies ...
Cached Medicine News:Health News:Pioneering Safe Medication Return Initiative Reviewed During Pharmaceutical Disposal Summit 2Health News:Longs Reports Preliminary May Retail Drug Store Sales 2Health News:MSA Cranberry Plant Named One of Safest in Country 2Health News:MSA Cranberry Plant Named One of Safest in Country 3Health News:Photos: The Multiple Sclerosis Association of America Produces a Web Video on the Importance of MRIs 2Health News:Kagome's Yellow Mango Orchard Blended Juice Named One of America's Healthiest Buys 2Health News:Kagome's Yellow Mango Orchard Blended Juice Named One of America's Healthiest Buys 3Health News:Demonstrating the Value of Benchmarking in an Uncertain Economy 2
(Date:7/30/2015)... -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today ... the second quarter ending June 30, 2015. ... organization.  We are excited to be near the completion ... conducted with topline results expected in the fourth quarter," ... Therapeutics, Inc. "Translarna is now commercially available in 12 ...
(Date:7/30/2015)... CHENGDU, China , July 30, 2015 ... "Company"), a pharmaceutical company that specializes in the patented ... active pharmaceutical ingredients (API), provided updates regarding the notice ... MKT LLC (the "Exchange") indicating that the Company was ... set forth in Sections 134 and 1101 of the ...
(Date:7/30/2015)... 30, 2015 Eisai Inc. announced today that ... United States , European Union and ... respectively) for eribulin, for the treatment of patients with ... chemotherapy for advanced or metastatic disease. ... pivotal global Phase 3 clinical trial (Study 309), which ...
Breaking Medicine Technology:PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5
... SUNNYVALE, Calif., Oct. 24, 2011 Accuray Incorporated (Nasdaq: ... that it will report results for its first quarter of ... 8, 2011 after the market closes. A conference ... fiscal year 2012 will begin at 2:00 p.m. PST/5:00 p.m. ...
... Awarepoint Corporation , the leading provider of ... the hiring of four senior management executives to support ... solutions in hospitals and clinics. Merrie Wallace, R.N., B.S.N., ... solutions, reporting to Awarepoint CEO Jay Deady. Chris Cosgrove ...
Cached Medicine Technology:Accuray Incorporated to Report Financial Results for First Quarter of Fiscal 2012 2Awarepoint Expands Senior Management Team 2Awarepoint Expands Senior Management Team 3
We offer small and large pre-gelled Surface Electrodes suitable for EGG or EMG recordings. Surface Electrodes, Skin Preparation and Conductive Cream complete the setup for a EGG study and are essenti...
We offer small and large pre-gelled Surface Electrodes suitable for EGG or EMG recordings. Surface Electrodes, Skin Preparation and Conductive Cream complete the setup for a EGG study and are essenti...
We offer small and large pre-gelled Surface Electrodes suitable for EGG or EMG recordings. Surface Electrodes, Skin Preparation and Conductive Cream complete the setup for a EGG study and are essenti...
... We have water perfused manometric ... vector volume diagnostic tests. All ... made using clear, medical grade ... in the esophagus you will ...
Medicine Products: